Wiley’s COVID-19 research freely available in publicly funded archives

HOBOKEN, N.J.–March 18, 2020–

John

Wiley

and Sons Inc. (NYSE: JW-A) (NYSE: JW-B), a global leader in research and education, is making all current and future research content and data on the


COVID-19 Resource Site


available to PubMed Central, the archive of biomedical and life science at the US National Institutes of Health’s National Library of Medicine. The research content is accessible in other publicly funded repositories, such as the World Health Organization (WHO) COVID-19 database and Wellcome Trust, for as long as needed.

The content is licensed so that researchers can apply text and data mining plus artificial intelligence techniques to maximize the usability of new coronavirus research as it’s published.

Judy Verses, Executive Vice President of Research says, “As the COVID-19 crisis continues, Wiley and its society partners are devoted to doing all we can to aid in the global response by delivering relevant research to scientists and practitioners on the front lines of the fight against this pandemic. A whole-of-system effort is critical, and we pledge to continue to join forces with the global community to advance research and support patient care.”

In early February, Wiley launched its COVID-19 Resource Site with free information that is updated daily with the latest research on the virus and includes links to more than 5,000 articles. Wiley, in partnership with Atypon, have also launched an

AI-driven real-time Scitrus feed

aggregating the latest research, preprints, and news on COVID-19.

###

About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company’s website can be accessed at

http://www.

wiley.

com

.

Wiley Contacts

Media Relations:

Dawn Peters (US): +1 781-388-8408


[email protected]